人前列腺癌细胞PC-3M亚系u-PAR基因表达的分析

目的 为研究与人前列腺癌细胞(PC-3M)侵袭能力相关的靶分子。方法 采用有限稀释法分离单克隆细胞株，并应用单层细胞侵袭等实验鉴定各亚系的体外侵袭能力；借助RT-PCR和免疫组化的方法，分别在转录和翻译水平检测5株侵袭能力不同的PC-3M亚系尿激酶型纤溶酶原激活物受体(u-PAR)的表达。结果 高侵袭亚系u-PAR基因mRNA的表达和蛋白质水平均明显高于低侵袭亚系。结论 PC-3M亚系u-PAR的高表达与其较强的侵袭能力密切相关，而u-PAR可能是抑制高侵袭亚系侵袭效应的一个重要靶分子。     

A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival

BACKGROUND: Dendritic cells are potent antigen-presenting cells that bind allogeneic T cells. They are thus candidates for targeting immunoregulatory molecules to the alloreactive T cell compartment and suppressing the alloimmune response. METHOD: A dendritic cell line derived from the BALB/c mouse (H2d) was genetically modified to express the immunoregulatory molecule CTLA4-Ig. The ability of these dendritic cell transfectants to downregulate the alloimmune response was tested in an islet transplant model. Allogeneic C57Bl/6 (H2b) mice were rendered diabetic with streptozocin, and they received BALB/c islet (H2d) transplants. Mice were administered 25 million untransfected or CTLA4-Ig-transfected D2SC/1 cells i.v. on the day of islet transplantation and 6 days later[fnc]. RESULT: Mice treated with CTLA4-Ig-transfected D2SC/1 cells demonstrated prolonged allograft survival (mean = 20 days, median = 17 days, SD = 9.39) compared with mice treated with untransfected D2SC/1 cells (mean = 12 days, median = 11 days, SD=2.74) or untreated control mice (mean = 11 days, median = 11 days SD = 1.41). Third party allograft survival was not prolonged in mice receiving similar treatment. CONCLUSIONS: These results demonstrate that a genetically modified dendritic cell line can suppress the alloimmune response and prolong islet allograft survival in an allospecific manner. The findings also suggest that genetically modified dendritic cells may be useful in targeting alloreactive T cells and prolonging allograft survival.     

Ability of a Specific ERK Signal-Pathway Inhibitor to Reverse P-Glycoprotein- Mediated Vincristine Resistance in Colon Cancer Cell Unes

OBJECTIVE To investigate the effect of a specific inhibitor PD098059 of the extracellular-signal regulated protein kinase (ERK) pathway on the P-glycoprotein (P-gp)-mediated resistance of colon cancer cell lines SW480/VCR and CoLo205NCR.METHODS SW480NCR and CoLo205NCR cells were generated byexposuring SW480 and CoLo205 cells to vincristine (VCR) (30 ng/ml) for 72h, which resulted in a comparatively higher level of P-gp expression.Western blotting was used to analyze P-gp, MRP, LRP, GST-‘rr and TOPOIIexpression after exposuring the SW480 and CoLo205 cells to VCR (30 ng/ml)for 72 hrs. P-gp and pERK1/2 expressions was analyzed in SW480NCR andCoLo205/VCR cells treated with or without the specific inhibitor of MEK,PD098059. The MTT assay was used to determine the susceptibility ofSW480NCR and CoLo205NCR cells to VCR, treated with or withoutPD098059.I~F.SULI“S The results showed that VCR induced a comparatively higher levelof P-gp expression in the cell lines, but not that of MRP, LRP, GST-n- orTOPOII. P-gp expression levels were depressed significantly in SW480/VCR and COLO205/VCR cells by the specific inhibitor of MEK, PD098059.The IC50 (248 19.6 and 215 10.7 ng/ml) to VCR of SW480/VCR andCoLo205/VCR cells exhibited a 2.16 and 2.03-fold higher resistancecompared to the negative control group (SW480 and CoLo205 cells)(115 15.6 and 106 11.9 ng/ml), but a 1.35 and 1.21 -fold higher resistance thanthe group treated with VCR (30 ng/ml) PD098059 (184 21.8 and 177 19.4 ng/ml).CONCLUSION This study shows that the expression of P-gp can beinduced by exposuring cells to VCR, and that this induction can be reversedby inhibiting the ERK signaling pathway at the point of MEK by its specificinhibitor, PD098059. The ERK signal-transduction pathway may play a rolein modulating mdrl expression in colon cancer.     

Acupuncture treatment of 32 cases of lumbar intervertebral disc protrusion

Yaoyangguan (GV 3), Shiqizhui (Ex-B 8) and Yanglingquan (GB 34) were selected as main points and a three-part needle insertion technique was used to treat 32 cases of lumbar intervertebral disc protrusion. The curative rate was 96.9%. Deep puncture is the key to the treatment. Author: Chen Feng(1962-), male, junior consultant doctor Translator: Wang Si-you     

Clinical observation of vascular dementia treated by surrounding-acupuncture of the CT-located area

Purpose To observe the clinical effect of “Surrounding Needling Technigue through CT Location” in treating vascular dementia.Method Fifty cases of vascular dementia were randomly divided into surrounding Needling Technigue through CT location and routine acupuncture groups, 25 cases in each group, and were given surrounding Needling Technigue through CT location and routine acupuncture respectively.Results The effective rates in surrounding Needling Technigue through CT location and routine acupuncture groups were 88% and 60% respectively, and there was significant difference between the two groups,P<0.01.Conclusion Therapeutic effect of surrounding Needling Technigue through CT location in treating vascular dementia was satisfactory, and better than that of routine acupuncture. Foundation Item: Scientific Fundation of Guangdong TCM Bureau Author: Lun Xin(1964-), male, associate professor     

Acupuncture plus herbal medicine treated 30 cases of minor chorea

In the treatment of 30 cases of minor chorea by puncturing Baihui (GV 20), Sishencong (Ex-HN 1) and Fengchi (GB 20), in combination of oral administration of herbal medicine, the total effective rate is 96.7%. Author: ZHANG Shu-jun (1961-), female, lecturer Translator: HUANG Guo-qi     

Marimastat对裸鼠原位种植人胃癌生长和转移抑制的实验研究

目的 探讨基质金属蛋白酶抑制剂Marimastat对胃癌生长和转移的抑制作用。方法 采用人胃腺癌细胞株SGC—7901完整组织块棵鼠原位种植，建立胃癌转移模型。移植7天后开始腹腔内注射Marimastat，隔天1次，剂量为0mg/kg(对照组)、10mg/kg、30mg/kg、60mg/kg(治疗组)，共用8周，第9周处死动物，测量原位肿瘤大小、抑瘤率、肿瘤微血管密度(MVD)、MMP—9的高表达率、观察肿瘤转移情况。结果 治疗组原位肿瘤瘤重明显较对照组轻，肿瘤肝脏转移、腹膜转移、肿瘤组织微血管密度和肿瘤组织MMP—9高表达率与对照组比较，均有显著性差异(P＜0．05)，且与Marimastat剂量呈正相关。结论 Marimastat对体内胃癌的生长及转移均有抑制作用。     

趋化因子受体CCR5在食管上皮癌变过程中作用的初步探讨

目的　探讨 CC趋化因子受体 5 (CCR5 )是否介导食管上皮炎性病变与其癌变过程的关系。方法　用免疫组化检测 40例食管鳞状细胞癌 (SCC)、癌旁炎症、不典型增生组织及 10例正常食管黏膜的 CCR5表达情况。结果　食管 SCC的 CCR5表达阳性率高于正常黏膜、慢性炎症及不典型增生的表达率 (P<0 .0 5 )。在 CCR5表达阳性的食管 SCC中 ,癌间质的单核淋巴细胞 CCR5阳性表达率分别低于癌旁炎症的单核淋巴细胞 CCR5阳性表达率(P<0 .0 5 )。结论　 CCR5在食管癌变进程中表达呈升高趋势 ,提示食管 SCC细胞可能通过表达 CCR5受体与间质浸润的单核细胞、淋巴细胞共同竞争趋化因子配体 ,从而实现了食管 SCC发生进程的免疫逃逸现象     

脊椎血管瘤手术后复发放射治疗疗效观察(附6例报告)

目的 探讨脊椎血管瘤手术后复发放射治疗疗效和适宜剂量。方法 1968—1992年间共收治手术后复发的有症状的脊椎血管瘤6例，中位年龄28岁。病灶在胸椎5例，腰椎1例。4例有病灶局部疼痛合并不完全性截瘫，2例为局部疼痛合并下肢麻木无力。采用^60Co和8MV—X线照射治疗，总剂量范围30-60Gy，平均40Gy。结果 所有接受放疗的患均获得良好的远期效果，4例不完全截瘫患中3例基本恢复，1例完全恢复，另外2例原有的下肢麻木症状消失，但影像学检查均无明显改变。结论 放射治疗对手术后复发的脊椎血管瘤是安全有效的，剂量以36—40Gy为宜。但放射治疗起效比较慢，且影像学改变不明显，所以应以远期症状改善率作为评价放射治疗效果的标准。     

38例腹膜后脂肪肉瘤的临床分析

目的 分析腹膜后脂肪肉瘤的治疗结果。方法 1958～1998年我院收治38例腹膜后脂肪肉瘤。21例为首程治疗,17例局部复发后再程治疗。21例初治患者均接受手术治疗,手术完整切除率为86％。3例接受术后放射治疗。17例外院术后复发再程治疗患者有13例在我院接受手术,4例接受单纯放疗。再程手术完整切除率为54％,1例接受术后放放射治疗。放疗剂量DT30Gy～70Gy,中位剂量50Gy。结果 全组患者5年总生存率为50％,5年远转率为7.3％,5年局部复发率为65％,初程治疗和再程治疗组的5年总生存率为53％和48％,无显著性差异(P=0.293,5年局部复发率为59％和74％,无显著差别(P=0.615)。全组手术完整切除组5年生存率为58％,部分切除或未切除者5年生存率为27％,有显著性差异(P=0.006)。34例有肿瘤大小记录的患者,其中4例肿瘤<10cm,均存活;22例肿瘤10～30cm,有13例死亡;8例肿瘤≥30cm,有6例死亡。结论 腹膜后脂肪肉瘤的治疗以手术为主,手术完整切除可显著提高生存率。经积极治疗,复发患者仍能取得很好的效果。